Linear growth (length/height) Unit: cm Time frame: 3 months · children under 5 years of age
1 finding from 1 review
Mean height‐for‐age z‐score · children under 5 years of age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Stuntingb · children under 5 years of age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effect: hypercalciuria As defined by trialists Time frame: 3 months · children under 5 years of age
Vitamin D (higher dose) + micronutrient(s) showed no clear difference in adverse effect: hypercalciuria As defined by trialists Time frame: 3… compared with vitamin D (lower dose) + micronutrient(s) (low certainty).
1 finding from 1 review
Hypercalcaemia · children under 5 years of age
Vitamin D (higher dose) + micronutrient(s) showed no clear difference in adverse effect: hypercalcaemia As defined by trialists Time frame:… compared with vitamin D (lower dose) + micronutrient(s) (moderate certainty).
1 finding from 1 review
Adverse effect: hyperphosphataemiab · children under 5 years of age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effect: kidney stonesb · children under 5 years of age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
sUA reduction · participants with chronic gout and sUA level > 0.36mmol/L
1 finding from 1 review
Joint pain reduction ‐ not reported · participants with chronic gout and sUA level > 0.36mmol/L
The review found no eligible studies for this question.
1 finding from 1 review
Participant global assessment · participants with chronic gout and sUA level > 0.36mmol/L
The review found no eligible studies for this question.
1 finding from 1 review
Total adverse events · participants with chronic gout and sUA level > 0.36mmol/L
1 finding from 1 review
Tophus regression · participants with chronic gout and sUA level > 0.36mmol/L
The review found no eligible studies for this question.
1 finding from 1 review
Acute gout attacks · participants with chronic gout and sUA level > 0.36mmol/L
The review found no eligible studies for this question.
1 finding from 1 review
Withdrawals due to adverse events · participants with chronic gout and sUA level > 0.36mmol/L
1 finding from 1 review
Incidence: lung cancer · healthy people and healthy male physicians
Vitamin A showed no clear difference in incidence: lung cancer compared with placebo (high certainty).
1 finding from 1 review
Incidence: lung cancer ‐ women · healthy male physicians, period: 1997 to 2007 and female health professionals, period: 1998 to 2005
Vitamin C leads to higher incidence: lung cancer ‐ women compared with placebo (high certainty).
1 finding from 1 review
Mortality: lung cancer ‐ men · healthy male physicians, period: 1997 to 2007 and female health professionals, period: 1998 to 2005
Vitamin C showed no clear difference in mortality: lung cancer ‐ men compared with placebo (high certainty).
1 finding from 1 review
Adverse events · healthy male physicians, period: 1997 to 2007 and female health professionals, period: 1998 to 2005
1 finding from 1 review
no estimate extracted
1 study · 1 participants
High
Incidence: all cancers · healthy male physicians, period: 1997 to 2007 and female health professionals, period: 1998 to 2005
Vitamin C showed no clear difference in incidence: all cancers compared with placebo (high certainty).
1 finding from 1 review
Mortality: all cancers · healthy male physicians, period: 1997 to 2007 and female health professionals, period: 1998 to 2005
Vitamin C showed no clear difference in mortality: all cancers compared with placebo (high certainty).
1 finding from 1 review